MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Medtech Giants Are Working to Enhance Cardiac Care in Southeast Asia

Science History Images / Alamy Stock Photo IMG_2022-1-5-131053.jpg
Boston Scientific and GE Healthcare are bringing their interventional cardiology portfolios to cardiac care centers.

Two medtech powerhouses are teaming up to enhance interventional cardiac care in Southeast Asia. Both GE Healthcare and Boston Scientific announced the collaboration Wednesday.  

The companies will bring their interventional cardiology portfolios to cardiac care centers in Southeast Asia.

Boston Scientific’s advanced medical devices and capabilities, coupled with GE Healthcare’s strong medical imaging systems like cardiac catherization lab and related software, support diagnosis to treatment and monitoring of the cardiac patient-care pathway.

“Our mission to transform lives through innovative medical solutions has played a key role in driving this collaboration with GE Healthcare, where we look forward to offering the broadest suite of solutions for today's interventional cardiologist in Southeast Asia. By integrating access to the latest medical innovations and cutting-edge technology for our joint customers and the patients they care for, we can ensure treatment of patients of all degrees of complexity is readily available,” said Min Hang Heo, Vice President, and Managing Director, Boston Scientific Korea and ASEAN.

“Bridging the industry gap in providing an end-to-end cardiac care center for healthcare providers, this partnership will see the integration of cardiac care solutions, from Cath labs to Intravascular Ultrasound (IVUS), serving as a comprehensive portfolio for heart surgeons,” said Chris Khang, President and CEO, GE Healthcare ASEAN.

The collaboration comes hot on the heels of major developments for both companies.

Marlborough, MA-Boston Scientific is in the middle of closing its $1.75 billion acquisition of Baylis Medical, a company that has developed the NRG and VersaCross Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access.

GE Healthcare is in the process of becoming its own public company. This is expected to happen in 2023 as part of a three-way split from GE that will create three public companies. GE said it will combine its renewable energy, power, and digital businesses into a separate company in a second spin-off slated for 2024. The remaining GE business will focus on aviation.

 

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish